Department of Chemistry, Korea Advanced Institute of Science and Technology, Daejeon 305-701, Korea.
Arch Pharm Res. 2011 May;34(5):699-701. doi: 10.1007/s12272-011-0521-5.
Melanoma has the capacity to spread via the blood stream to the brain, and has been notoriously resistant to drug therapy. An activating mutation in the gene encoding BRAF is known to be responsible for half of melanomas. This article provides a review of GSK2118436 and PLX4032 as potential therapeutics for the treatment of melanomas by inhibiting oncogenic BRAF.
黑色素瘤有通过血液传播到大脑的能力，并且一直对药物治疗具有很强的耐药性。已知编码 BRAF 的基因中的激活突变负责一半的黑色素瘤。本文综述了 GSK2118436 和 PLX4032 作为通过抑制致癌 BRAF 治疗黑色素瘤的潜在治疗药物。
